Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
Primary arterial hypertension (AH) or essential hypertension (AH) remains one of the most common cardiovascular diseases. A prolonged and persistent increase in blood pressure (BP) leads to damage to target organs, contributing to the development of severe cardiovascular complications (cerebral stroke, myocardial infarction, life-threatening arrhythmias and heart failure), kidney damage (renal failure) and vision and causes high mortality and disability of the working-age population. Annually in the world hypertension is the cause of death of more than 10 million people. In Ukraine, more than 12.6 million people are registered with this disease, or more than 35% of the population. But, among people with high blood pressure (BP), only 52% of patients know about the presence of the disease, less than a third of them are treated, and no more than 15% of patients are effectively treated.
“For the second month, we see an increase in the number of coronavirus diseases. Over the past week, 24,000 new cases were recorded, the week before that there were 16,000, that is, there is a gradual increase. Our experts, together with WHO experts, predict that this year the peak incidence will be at the beginning October... In previous years, it was the end of October - the beginning of November. We are preparing for this in order to provide proper medical care," the minister said.
The current COVID-19 pandemic caused by SARS-CoV-2 has become a global health emergency. Treatment of chronic inflammatory bowel disease (CIBD) according to the standards includes the use of 5-aminosalicylic acid (5-ASA), corticosteroids, cytostatics, and biological therapy. However, these treatments can weaken the immune system, which potentially puts COPD patients at increased risk of infections and infectious diseases, including COVID-19. Therefore, patients with CVD have a greater risk of developing COVID-19 and more severe clinical course, or even death, compared to the general population.
Treatment with corticosteroids (especially prednisolone ≥20 mg/day or equivalent) is associated with an increased risk of infection. However, it is unclear whether corticosteroid therapy is associated with an increased risk of developing COVID-19 or its complications. Data on budesonide, a topical corticosteroid with low systemic bioavailability, show that these drugs are associated with significantly fewer side effects compared to systemic corticosteroids and their side effects are close to placebo. If possible, corticosteroids should be avoided and a rapid dose reduction considered, and a switch to budesonide is recommended. This must be taken into account, taking into account the risk of exacerbation of CKD. If a patient with COPD is in contact with a person with COVID-19 or develops COVID-19, it is recommended to gradually reduce the dose of corticosteroids, the use of budesonide is preferred, but taking into account the severity of COPD and the risk of exacerbation.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием